Results 51 to 60 of about 2,000 (177)

Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir

mBio, 2022
Lenacapavir (LEN) is a long-acting, highly potent HIV-1 capsid (CA) inhibitor. The evolution of viral variants under the genetic pressure of LEN identified Q67H, N74D, and Q67H/N74D CA substitutions as the main resistance associated mutations (RAMs ...
Stephanie M. Bester, Daniel Adu-Ampratwum, Arun S. Annamalai, Guochao Wei, Lorenzo Briganti, Bridget C. Murphy, Reed Haney, James R. Fuchs, Mamuka Kvaratskhelia   +8 more
doaj   +1 more source

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

Clinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian, Moherndran Archary, Daniel B. Hawcutt, Rachel Daley, Edmund Capparelli, Adeniyi Olagunju   +5 more
wiley   +1 more source

Real‐world use and effectiveness of fostemsavir in a US clinical setting: Insights from Trio Health HIV Research Network

HIV Medicine, EarlyView.
Abstract Objective To describe real‐world patterns of use, virologic and immunologic outcomes and treatment persistence among people with HIV (PWH) initiating fostemsavir (FTR) in a diverse US cohort. Design Retrospective cohort study of adults receiving FTR in clinical practice, stratified by baseline viral suppression status.
Richard Elion, Cassidy Henegar, Isobel McEwen, Andrew Frick, Moti Ramgopal, Steven Santiago, Karam Mounzer, Gregory Huhn, Charles Walworth, Leigh Ragone, Vani Vannappagari   +10 more
wiley   +1 more source

Preparation of a key intermediate en route to the anti-HIV drug lenacapavir [PDF]

, 2023
A very efficient 4-step synthesis of the main fragment of Gilead’s anti-HIV drug lenacapavir is described. The route showcases a 1,2-addition to an intermediate aldehyde using an organozinc halide derived from a commercially available difluorobenzyl ...
Yuting, Hu, Bruce, Lipshutz, Kirabel, Mamo, Juan , Caravez, Erfan, Oftadeh   +4 more
core   +2 more sources

Novel dolutegravir and lenacapavir resistance patterns in human immunodeficiency virus type 2 infection : a case report [PDF]

Background The treatment management of human immunodeficiency virus (HIV)-2 infection presents greater challenges compared to HIV-1 infection, primarily because of inherent resistance against non-nucleoside reverse transcriptase inhibitors.
van de Vijver, David A M C, Voskamp, Mike, van Kampen, Jeroen J A, Gruters, Rob A; id_orcid, Charpentier, Charlotte, Mahmud, Rizwan, van de Vijver, David A M C; id_orcid, Nijssen, Tess, Krullaars, Zoë, Le Hingrat, Quentin, van Nood, Els, Nijssen, Tessel F., Voskamp, Tess, Gruters, Rob A, Voermans, Jolanda J C, Mesplède, Thibault   +15 more
core   +1 more source

Predicting Oral HIV Pre‐Exposure Prophylaxis Efficacy in Cisgender Women Across Pregnancy and Postpartum

The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract Cisgender women face an increased risk of HIV acquisition during pregnancy and postpartum. Oral pre‐exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate (F/TDF) is recommended in pregnancy despite limited published pharmacokinetic (PK) and efficacy data during pregnancy.
Yifan Yu, Kristina M. Brooks, Gustavo F. Doncel, Brookie M. Best, Mark A. Marzinke, Mark Mirochnick, Peter L. Anderson, Landon Myer, Connie Celum, Renee Heffron, Jenell Coleman, Dvora L. Joseph Davey, Lanxin Zhang, Max von Kleist, Craig W. Hendrix, Jeremiah D. Momper, Robert Bies, Rachel K. Scott   +17 more
wiley   +1 more source

Spatiotemporal binding of cyclophilin A and CPSF6 to capsid regulates HIV-1 nuclear entry and integration

mBio
Human immunodeficiency virus type 1 (HIV-1) capsid, which is the target of the antiviral lenacapavir, protects the viral genome and binds multiple host proteins to influence intracellular trafficking, nuclear import, and integration.
Zachary Ingram, Christopher Kline, Alexandra K. Hughson, Parmit K. Singh, Hannah L. Fischer, Rajalingham Radhakrishnan, Gregory A. Sowd, Nayara F. B. Dos Santos, Barbie K. Ganser-Pornillos, Simon C. Watkins, Melissa Kane, Alan N. Engelman, Zandrea Ambrose   +12 more
doaj   +1 more source

Comparing Approaches for Estimating Counterfactual HIV Incidence Among Populations With High Vulnerability to HIV in Lima, Peru: A Multi‐Study Comparative Analysis

Journal of the International AIDS Society, Volume 29, Issue 9, September 2026.
ABSTRACT Introduction The availability of highly efficacious HIV pre‐exposure prophylaxis (PrEP) makes it unethical or infeasible to conduct inactive/placebo‐controlled trials to evaluate new HIV prevention options. As a result, randomized active‐control non‐inferiority trials are typically employed; however, they require large sample sizes and ...
Fei Gao, Sayan Dasgupta, Siavash Pasalar, Qi Wang, Ricardo Alfaro, Delia Pinto‐Santini, Thiago S. Torres, Jorge Sanchez, Javier R. Lama, Valdilea G. Veloso, Michal Juraska, Robinson Cabello, Jorge O. Alarcon, Beatriz Grinsztejn, Carlos F. Caceres, James F. Rooney, Ann Duerr   +16 more
wiley   +1 more source

Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxis

The Lancet HIV
Although drug resistance could emerge if lenacapavir is initiated during undiagnosed acute infection or if infection occurs during the drug’s pharmacokinetic tail, these cases will not compromise the effectiveness of WHO-recommended therapies, as there ...
G. V. van Zyl, Mateo Prochazka, H. Schmidt, C. Orrell, J. Schapiro, Suzanne M McCluskey, Marco Vitoria, Rami Kantor, Urvi M. Parikh, M. Rodolph, Michael R. Jordan, Robert W. Shafer   +11 more
semanticscholar   +1 more source

Effect of a Peer Support Intervention for Oral Pre‐Exposure Prophylaxis Uptake and Adherence Among Adolescent Girls and Young Women at Risk of HIV Acquisition in Kampala, Uganda: A Randomized Controlled Trial

Journal of the International AIDS Society, Volume 29, Issue 9, September 2026.
ABSTRACT Introduction Daily oral pre‐exposure prophylaxis (PrEP) use remains low among adolescent girls and young women (AGYW). We evaluated whether a peer support intervention improved daily oral PrEP uptake and adherence among AGYW at high risk of HIV acquisition in Kampala, Uganda.
Yunia Mayanja, Andrew Abaasa, Kenneth Roger Katumba, Matthew Spinelli, Bernard Kikaire, Monica Gandhi, Kyriaki Kosidou, Anna Mia Ekstrom, Eugene Ruzagira   +8 more
wiley   +1 more source